医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ketamine Clinic in Japan for Inbound Medical Treatment: Nagoya Anesthesia Clinic

2023年11月14日 AM09:00
このエントリーをはてなブックマークに追加


 

NAGOYA, Japan

Nagoya Anesthesia Clinic (https://nagoyamasui.com/2-2), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disorders, and intractable chronic pain, utilizing the groundbreaking drug Ketamine. Over the past 15 years, the clinic has provided ketamine therapy through more than 1300 ketamine infusions. Our distinctive approach to addressing pain and depression includes a simultaneous cervical epidural block, with successful implementation in over 250 cases, and hypnotherapy during ketamine infusion. Additionally, the clinic offers innovative procedures such as Echo-Guided Botox treatment for stiff neck and Echo-Guided PRP therapy for tennis elbow.

Ketamine, a widely used general anesthetic with a history dating back over 50 years, has also been employed in the United States for the treatment of mental disorders and chronic pain for the past decade. Unlike conventional medications, which may take time to alleviate symptoms, Ketamine offers rapid relief within hours to up to three weeks of administration. Moreover, it is associated with minimal long-term side effects, making it a promising treatment option.

Drawing on their extensive experience of performing Ketamine infusions for various pain and mental disorders, Nagoya Anesthesia Clinic has established the Ketamine Clinic based on Ketamine’s potent analgesic and antidepressant properties. Typically, ketamine infusions are administered in sets of 3 to 6 sessions over a span of 1 to 3 weeks, followed by a maintenance therapy once a month, known for its low incidence of long-term side effects.

Nagoya Anesthesia Clinic is dedicated to provision of exceptional care and innovative treatments to patients in Japan and beyond, welcoming patients for inbound medical treatment of treatment-resistant depression, OCD, PTSD, and intractable chronic pain starting from October 2023. Building on their extensive ketamine infusion experience, the clinic aims to support individuals coping with treatment-resistant conditions through innovative, evidence-based, and compassionate approaches.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231113434750/en/

CONTACT

For inquiries, please contact:

JTB Medical & Healthcare:

jmhc_info@j-medical-healthcare.com

同じカテゴリーの記事 

  • Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D
  • Takeda公布2023财年全年业绩和2024财年展望,确认对后期研发管线开发和提高核心营业利润率的承诺
  • Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
  • AMLにおける寛解期に残存するFLT3-ITD変異と移植後の転帰との間に重要な関連があることが研究によって判明
  • 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系